Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.

Journal of pharmacokinetics and pharmacodynamics - 1 Apr 2008

Elsherbiny Doaa A, Asimus Sara A, Karlsson Mats O, Ashton Michael, Simonsson Ulrika S H

Abstract excerpt

The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. The population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, including enzyme turn-over models for induction, were described by nonlinear mixed effects modeling. Rich data (8-16 samples/occasion/subject) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Artemisinins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Cytochrome P-450 CYP2B6

Share to Drug Combinations

Share to Enzyme Induction

Share to Mephenytoin

Share to Oxidoreductases, N-Demethylating

Source

Identifiers

PMID: 18350255
DOI: 10.1007/s10928-008-9084-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.PMID 18350255Read ↗

Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.Semantic proximity Read ↗

Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.Semantic proximity Read ↗

Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.Semantic proximity Read ↗

Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugsSemantic proximity Read ↗

Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-HydroxylationSemantic proximity Read ↗

Development and characterization of pFluor50, a fluorogenic-based kinetic assay system for high-throughput inhibition screening and characterization of time-dependent inhibition and inhibition type for six human CYPsSemantic proximity Read ↗

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.Semantic proximity Read ↗

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.Semantic proximity Read ↗

In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations.Semantic proximity Read ↗

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.Semantic proximity Read ↗

Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects.Semantic proximity Read ↗

Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.